Three mechanisms, one injectable scaffold

Patients often ask the same question before their first consultation: does ChondroFiller® inject cartilage into the joint? It does not. Instead, it creates the structural and biological conditions for the body to form its own repair tissue — through three sequential, interdependent processes that begin the moment the gel contacts the defect.

The scaffold itself is acellular: it contains no donor cells and no lab-grown tissue, so no prior biopsy is needed. Treatment is delivered as a single ultrasound-guided outpatient injection; the gel forms inside the joint, not outside it. This overall process is known as acellular matrix-induced chondrogenesis (ACIC) — a term worth holding onto, because it names what distinguishes ChondroFiller® from both simple viscosupplementation and cell-transplant procedures.

The three mechanisms are:

• In-situ gelation — the scaffold sets at the defect site, conforming to its contours
• Progenitor cell recruitment — the porous matrix draws the patient's own repair cells inward
• Catabolic suppression — the combined environment shifts the joint away from active cartilage breakdown

Each is covered in turn below.

pH-triggered gelation: how the scaffold forms in the joint

The engineering behind ChondroFiller® is straightforward once you understand one key idea: the collagen is kept chemically 'switched off' until it reaches the joint.

The product is supplied in a dual-chamber syringe — one side holding the collagen in an acidic storage solution, the other holding a neutralising agent. When the clinician depresses the plunger during the ultrasound-guided injection, a mixing adapter at the tip combines both solutions for the first time. That shift in acidity — from the acidic storage state toward the body's natural pH — is the sole trigger for the collagen fibres to begin self-assembling into a gel. No heating is required, and no synthetic bonding agent (crosslinker) is added; the collagen simply behaves as native Type I collagen does at physiological pH, knitting into a stable, porous three-dimensional structure within minutes of entering the joint.

Because the gel forms at the defect site rather than being pre-formed outside the body, it conforms precisely to the contours of the cavity — including irregular shapes that a pre-cut implant could not fill. The resulting scaffold is load-bearing and provides an immediate physical presence at the lesion.

For patients with more diffuse cartilage wear — such as those with Kellgren-Lawrence Grade IV osteoarthritis — this high-viscosity, rapidly setting material can also lay down as a protective mechanical cushion over the worn articular surface, a role that extends its usefulness beyond strictly contained focal defects.

As new tissue matures within the scaffold over subsequent months, the collagen matrix is gradually broken down and cleared by the body, leaving no permanent synthetic material behind.

Recruiting the body's own repair cells

Once the gel has set, it begins its second task: acting as a biological invitation. The porous three-dimensional architecture of the scaffold creates a network of interconnected spaces into which mesenchymal stem cells (MSCs) and chondrocytes from surrounding healthy tissue and the subchondral bone can migrate and be retained. No cells are introduced from outside — the scaffold's role is structural and chemotactic, providing both a physical template and the biochemical signals that prompt the body's own progenitor cells to home in on the defect site.

Once inside, those cells undergo chondrogenic differentiation: they shift from their migratory state to an actively building one, depositing proteoglycans and Type II collagen — the molecular hallmarks of hyaline cartilage.

The distinction from microfracture is clinically meaningful. Microfracture also draws marrow-derived cells to a defect, but the repair tissue it generates is predominantly fibrocartilage — a stiffer, more fibrous material with poorer load-distribution properties and lower long-term durability. The structured collagen environment appears to guide differentiation toward hyaline-like tissue rather than this inferior substitute, which matters most in joints subject to repetitive loading.

Imaging evidence supports this. MOCART scores — a validated MRI-based measure of repair tissue quality, distinct from any symptom or function score — reach 70 to 87 in published matrix-based cohorts, indicating objectively visible improvement in cartilage appearance and composition. The body does the regenerative work; the scaffold simply gives it the right conditions in which to do so.

MMP-13 suppression: shifting the joint away from cartilage breakdown

Cartilage erosion in osteoarthritis is an active process, not simply mechanical wear. MMP-13 — matrix metalloproteinase-13 — is the enzyme primarily responsible for destroying Type II collagen in arthritic joints, and its concentration in joint tissue reflects how aggressively that catabolic process is running. Reducing MMP-13 activity is therefore a meaningful molecular signal, not merely a surrogate endpoint.

The most direct clinical evidence for ChondroFiller®'s effect on this pathway comes from a prospective controlled trial published in June 2025 by Weninger et al. (Gavin Publishers). The study enrolled 25 patients with Kellgren-Lawrence Grade IV knee osteoarthritis — a group with severe, established joint disease — and assigned them to receive either autologous blood-derived MSC concentrate alone (n=12) or MSC concentrate combined with ChondroFiller® liquid (n=13). At two months, both groups showed statistically significant improvement across all KOOS subscales (p<0.01). The combination group additionally showed a significantly greater reduction in MMP-13 expression than the MSC-only group — a finding that points to the scaffold contributing something beyond what the cell therapy alone delivered.

What the trial does not resolve is the scaffold's independent contribution. The comparison is ChondroFiller-plus-MSCs against MSCs alone; ChondroFiller in isolation was not tested, and its separate effect on MMP-13 has not yet been disaggregated from the combination. That is a genuine gap in the current evidence.

What the data do confirm is that adding ChondroFiller® to an autologous MSC graft shifted measurable catabolic enzyme activity further than the graft by itself — consistent with the scaffold helping to move the joint microenvironment from a state of active matrix breakdown toward one more conducive to repair.

What the evidence base currently supports

The evidence behind ChondroFiller® falls into three tiers of current certainty — a distinction worth holding onto when reviewing the literature.

Functional outcomes are the most established. In knee cohorts, IKDC scores improve by approximately 30 points at one year across published series; pooled responder rates across joints reach 70–85%. A proportion of this data comes from manufacturer-sponsored studies — not grounds for dismissal, but a factor to weigh when interpreting the figures.

Imaging data add objective support. MOCART scores of 70–87 appear in published matrix-based cohorts, corroborating the functional picture with measurable changes in repair tissue quality visible on MRI.

The molecular evidence is at an earlier stage. The June 2025 Weninger trial (n=25, KL Grade IV) provides the most direct data on MMP-13 suppression, but two months is a short follow-up window, and the scaffold was assessed within a combination protocol rather than in isolation. Longer-term molecular studies and trials disaggregating the scaffold's independent contribution remain outstanding.

One point applies across all three evidence streams: because the scaffold is progressively resorbed as new tissue matures, durability depends entirely on the quality of host repair tissue generated. That is consistent with the regenerative design — but it is a meaningful consideration when weighing whether this approach suits a particular clinical picture, which a specialist assessment is best placed to determine.

Whether ChondroFiller suits your joint

The practical question most patients arrive with is simple: is ChondroFiller® right for my joint? The honest answer is that it depends on defect size, disease stage, and the specific joint involved — variables that imaging and clinical examination clarify far more reliably than any self-referral checklist.

ChondroFiller® has been studied across both focal post-traumatic defects and diffuse osteoarthritis up to Kellgren-Lawrence Grade IV. At London Cartilage Clinic on Harley Street, suitability is assessed by Professor Paul Y. F. Lee, who reviews imaging, symptom history, and prior treatment before determining whether ChondroFiller® alone — or in combination with an autologous biologic such as BMAC or MSC concentrate — represents the better-evidenced route for that individual. Because the treatment is delivered as an outpatient injection under ultrasound guidance, no surgical pre-assessment is required before that conversation can begin.

To find out whether ChondroFiller® is appropriate for your joint, you can book an initial consultation at londoncartilage.com.